Survival rates for cancer are on the rise

Advancements in the treatment of cancer have resulted in a steady decline in the number of people who die due to this disease each year. Researchers feel that there will be about 1.3 million cancer related fatalities this year which is about a 10% decline from the confirmed death rates in 2007 which is the last year for which the WHO has death rate data for most countries in the EU.

A study of all types of cancers across 27 EU bloc countries found that men were more likely to die from cancer than were women. The research conducted by a team of scientists from Italy and Switzerland and published in the Annals of Oncology journal has predicted that cancer death rate of 139 per 100,000 men and 85 per 100,000 women in 2012 in the EU. It has been found that the most lethal cancers were those of the lung for men and breast for women and that one of the main reasons behind the lowering incidence of death resulting from cancer amongst women is the fact that there have been many advances in the prevention, detection and treatment of breast cancer. The largest cause for lung cancer has been smoking in both its active and passive forms, as there has been a decrease in the numbers of people who smoke over the past few years, there has been a concurrent decrease in lung cancer death rates as well.

Unfortunately most of these advancements in treating cancer come at a very high cost and even in developed countries cancer care is becoming increasingly unaffordable at a personal as well as state level, with a huge burden falling on private insurers as well as government funded health plans.

Interestingly there has been a steady increase in the rates of people suffering from pancreatic cancer in men as well as women in the EU, with 7.86 cases per 100,000 men in 2007 and 8.01 in 2012, and 5.24 and 5.38 per 100,000 respectively amongst women. It is felt that this has been due to the rising incidence in obesity in the general population as well as better diagnosis.

Leave a Reply


Switch to our mobile site